Statistics

Total Visits

Views
Weekly cabazitaxel in "unfit" metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment. CABASEM-SOGUG phase II trial43

Select a period of time:

Number of views in the range

Views
Weekly cabazitaxel in "unfit" metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment. CABASEM-SOGUG phase II trial31

Views

Views
March 20254
April 20252
May 20251
June 20251
July 202521
August 20252
September 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Brazil10
United States7
Singapore4
Argentina1
Chile1
Colombia1
Ecuador1
Spain1
United Kingdom1
Honduras1
 

Top cities views

Views
Porto Alegre2
Cape Town1
Chaguanas1
Charlotte1
Columbia1
Council Bluffs1
Curitiba1
Curvelo1
El Progreso1
Elmont1